Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review

J Dermatolog Treat. 2023 Dec;34(1):2279901. doi: 10.1080/09546634.2023.2279901. Epub 2023 Nov 9.ABSTRACTLangerhans cell histiocytosis (LCH) is a histiocytic neoplasm characterized by a mass of CD1a + CD207 + histiocytes, exhibiting a diverse range of clinical manifestations from a self-healing rash or single bone destruction to multi-organ disease with potentially fatal consequences. The identification of MAPK signaling pathway activation, particularly BRAFV600E mutations, has propelled targeted therapy into the forefront of therapeutic research for LCH. Several studies have demonstrated that Vemurafenib, a BRAF inhibitor, exhibits superior clinical efficacy and a more favorable safety profile in LCH. Herein, in this case report, we present a good response to vemurafenib in an infant diagnosed with multisystem Langerhans cell histiocytosis (LCH).PMID:37941458 | DOI:10.1080/09546634.2023.2279901
Source: Journal of Dermatological Treatment - Category: Dermatology Authors: Source Type: research